Cargando…

Non-genetic adaptive resistance to KRAS(G12C) inhibition: EMT is not the only culprit

Adaptions to therapeutic pressures exerted on cancer cells enable malignant progression of the tumor, culminating in escape from programmed cell death and development of resistant diseases. A common form of cancer adaptation is non-genetic alterations that exploit mechanisms already present in cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ning, Wenjuan, Marti, Thomas M., Dorn, Patrick, Peng, Ren-Wang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722758/ https://www.ncbi.nlm.nih.gov/pubmed/36483040 http://dx.doi.org/10.3389/fonc.2022.1004669

Ejemplares similares

A Breakthrough Brought about by Targeting KRAS(G12C): Nonconformity Is Punished
por: Ning, Wenjuan, et al.
Publicado: (2022)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
por: Qunaj, Lindor, et al.
Publicado: (2023)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
por: Bannoura, Sahar F., et al.
Publicado: (2022)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Serotonin syndrome: SSRIs are not the only culprit
por: Garel, Nicolas, et al.
Publicado: (2021)

Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis
por: Vu, Trung, et al.
Publicado: (2017)

Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models
por: Wan, Yuhua, et al.
Publicado: (2020)

Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS(G12C)
por: Zhuang, Haiming, et al.
Publicado: (2022)

Corrigendum: The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2022)

Hypoxia, partial EMT and collective migration: Emerging culprits in metastasis
por: Saxena, Kritika, et al.
Publicado: (2020)

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
por: Osterlund, Emerik, et al.
Publicado: (2022)

Serum-Based KRAS(G12/G13) Mutation Detection Using Droplet Digital PCR: Clinical Implications and Limitations in Colorectal Adenocarcinoma With Tumor Heterogeneity
por: Kim, Ju Seok, et al.
Publicado: (2021)

Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?
por: Alsalahi, Omran, et al.
Publicado: (2015)

Is inhaled glucocorticoids the only culprit in angina bullosa hemorrhagica?
por: Yorulmaz, Ahu, et al.
Publicado: (2018)

KRAS-specific antibody binds to KRAS protein inside colorectal adenocarcinoma cells and inhibits its localization to the plasma membrane
por: Lam, Kuen Kuen, et al.
Publicado: (2023)

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
por: Kitai, Hidenori, et al.
Publicado: (2016)

EMT or EMT-Promoting Transcription Factors, Where to Focus the Light?
por: Ansieau, Stéphane, et al.
Publicado: (2014)

Bcl-xL Is a Key Mediator of Apoptosis Following KRAS(G12C) Inhibition in KRAS(G12C)-mutant Colorectal Cancer
por: Khawaja, Hajrah, et al.
Publicado: (2023)

Is Gluten the Only Culprit for Non-Celiac Gluten/Wheat Sensitivity?
por: Mumolo, Maria Gloria, et al.
Publicado: (2020)

Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
por: Tsai, Yihsuan S., et al.
Publicado: (2022)

Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition
por: Huynh, Minh V., et al.
Publicado: (2022)

Germline Variants and Genetic Interactions of Several EMT Regulatory Genes Increase the Risk of HBV-Related Hepatocellular Carcinoma
por: Liu, Wen-Xuan, et al.
Publicado: (2021)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

When Stress Is Not the Only Culprit: A Case of Secondary Adrenal Insufficiency in a Young Patient With Graves’ Disease
por: Ozair, Saleha, et al.
Publicado: (2023)

Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras(G12V) mice
por: Kumar, Gaurav, et al.
Publicado: (2021)

Combined KRAS(G12C) and SOS1 inhibition enhances and extends the anti-tumor response in KRAS(G12C)-driven cancers by addressing intrinsic and acquired resistance
por: Thatikonda, Venu, et al.
Publicado: (2023)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Long Non-coding RNAs Contribute to the Inhibition of Proliferation and EMT by Pterostilbene in Human Breast Cancer
por: Huang, Yongye, et al.
Publicado: (2018)

EMT Factors and Metabolic Pathways in Cancer
por: Georgakopoulos-Soares, Ilias, et al.
Publicado: (2020)

KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population
por: Fancelli, Sara, et al.
Publicado: (2022)

Percutaneous Intervention in ST-Elevation Myocardial Infarction: Culprit-only or Complete Revascularization?
por: Osório, Ana Paula Susin, et al.
Publicado: (2017)

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
por: Yang, Haitang, et al.
Publicado: (2019)

DYNLT3 overexpression induces apoptosis and inhibits cell growth and migration via inhibition of the Wnt pathway and EMT in cervical cancer
por: Zhang, Jianan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_07pvfq7f7k834v1l8bu1t2ja1n